SUNNYVALE, Calif., Nov. 17, 2022 /PRNewswire/ — EBR Systems, Inc. (ASX: “EBR”, “EBR Systems”, or the “Company”), developer of the world’s only wireless cardiac pacing system for heart failure, is pleased to announce that the Company’s WiSE® technology will be featured at the 15th Asia Pacific Heart Rhythm Society (APHRS) Scientific Session in Singapore from the 18th to the 20th of […]
Coronary/Structural Heart
ENDONOVO ANNOUNCES PLAN TO EXPLORE STRATEGIC ALTERNATIVES FOR ITS SOFPULSE® MEDICAL DEVICE ASSETS
Los Angeles, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced plans to explore strategic alternatives to maximize the shareholder value potential of its SofPulse® Pulsed Electro Magnetic Frequency (PEMF) proprietary assets. This may include, but is not limited to, discussions with investment bankers, equity fund […]
Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research
Phase 1 results showed that AV-101 was generally well tolerated with significantly reduced systemic exposure compared to oral imatinib in healthy adult participants WALTHAM, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of […]
Impulse Dynamics Announces 100th Implant Milestone in China for CCM® Therapy
Experience Continues to Show CCM Therapy Addresses Clinical Need in Treating Heart Failure MARLTON, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure, announced the 100th implant in China, signifying the opportunity for its innovative Optimizer® […]
The CorVista® Analysis Provides a Robust Prediction for Elevated Left Ventricular End Diastolic Pressure at the Point-Of-Care
IDENTIFY Study Results Published in PLOS ONE WASHINGTON–(BUSINESS WIRE)–CorVista Health, Inc, a digital health company dedicated to improving cardiovascular disease diagnosis, announces the publishing of the IDENTIFY Study in PLOS ONE, the multicenter validation of a machine learned (ML) phase space electro-mechanical pulse wave analysis to predict elevated left ventricular end […]
Cardio Diagnostics Named to Fast Company’s Second Annual List of the Next Big Things in Tech
List Recognizes Tech Breakthroughs Across Industries That Promise to Transform the Future CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics (Nasdaq: CDIO), a precision cardiovascular disease company, today announced that it has been named to Fast Company’s second annual Next Big Things in Tech list, honoring technology breakthroughs that promise to shape the future of industries—from agriculture and environment […]
LivaNova Receives 510(k) Clearance for ECMO from FDA for LifeSPARC, the Next-generation Advanced Circulatory Support System
Platform simplifies life support, making life-saving technology more accessible to hospitals and critically ill patients LONDON–(BUSINESS WIRE)–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received 510(k) clearance for extracorporeal membrane oxygenation (ECMO) from the U.S. Food and Drug Administration (FDA) for LifeSPARC™, the Company’s […]
Verve Medical Announces Results of Feasibility Trial for Transurethral Renal Pelvic Denervation for Uncontrolled Hypertension
Study of the Verve RPD™ Renal Pelvic Denervation System Shows 20.3 mm Hg Reduction in Blood Pressure in Patients with Uncontrolled Hypertension PHOENIX–(BUSINESS WIRE)–Verve Medical, Inc. (“Verve”) today announced the detailed results from a feasibility trial evaluating a novel ablation therapy that achieved therapeutically significant blood pressure (“BP”) reduction for […]
Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 15 November 2022, 07:00 am CET Data from SAHARA with first-generation DSR product (DSR 1.0) confirm: Safe, effective and rapid elimination of persistent congestion following intensive DSR therapy Considerable benefit in cardio-renal status maintained till end of study (16 weeks post-intensive DSR therapy) Dramatic and sustained improvement in diuretic response up to 15 months post […]
MemorialCare Medical Group Nationally Recognized by the American Heart Association and American Medical Association for Type 2 Diabetes and Blood Pressure Cases
LONG BEACH, Calif., Nov. 14, 2022 /PRNewswire/ — MemorialCare Medical Group has received the American Heart Association’s Get With The Guidelines® – Target: Type 2 DiabetesSM Gold Certificate of Recognition, as well as the American Heart Association/American Medical Association’s Get With The Guidelines® – Target BPTM Gold Plus Quality Achievement Award. The awards celebrate MemorialCare Medical Group’s commitment […]


